MedTrace Logo

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

NCT03592706 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-04-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in：

1. Reduction of tumor size
2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.

Conditions

Interventions

BIOLOGICAL

IKC (Immune Killer Cells)

PROCEDURE

TACE (Transcatheter Arterial Chemoembolization)

Sponsors & Collaborators

  • Tri-Service General Hospital

    collaborator OTHER

  • Ivy Life Sciences, Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Chung-Bao Hsieh, MD · Tri-Service General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2021-02-28
Completion
2021-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03592706 on ClinicalTrials.gov